MENU
+Compare
BMY
Stock ticker: NYSE
AS OF
Sep 3 closing price
Price
$47.50
Change
+$0.09 (+0.19%)
Capitalization
96.68B

BMY Bristol-Myers Squibb Co Forecast, Technical & Fundamental Analysis

Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders... Show more

BMY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for BMY with price predictions
Sep 03, 2025

Aroon Indicator for BMY shows an upward move is likely

BMY's Aroon Indicator triggered a bullish signal on August 29, 2025. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 207 similar instances where the Aroon Indicator showed a similar pattern. In of the 207 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where BMY's RSI Oscillator exited the oversold zone, of 31 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

BMY moved above its 50-day moving average on August 29, 2025 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for BMY crossed bullishly above the 50-day moving average on August 20, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where BMY advanced for three days, in of 308 cases, the price rose further within the following month. The odds of a continued upward trend are .

BMY may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on August 27, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on BMY as a result. In of 91 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for BMY turned negative on August 28, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BMY declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.546) is normal, around the industry mean (9.456). P/E Ratio (19.076) is within average values for comparable stocks, (23.844). Projected Growth (PEG Ratio) (1.120) is also within normal values, averaging (1.757). BMY has a moderately high Dividend Yield (0.052) as compared to the industry average of (0.028). P/S Ratio (2.025) is also within normal values, averaging (3.426).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. BMY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BMY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 79, placing this stock worse than average.

View a ticker or compare two or three
BMY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

BMY is expected to report earnings to rise 15.75% to $1.69 per share on October 30

Bristol-Myers Squibb Co BMY Stock Earnings Reports
Q3'25
Est.
$1.69
Q2'25
Beat
by $0.40
Q1'25
Beat
by $0.28
Q4'24
Beat
by $0.20
Q3'24
Beat
by $0.30
The last earnings report on July 31 showed earnings per share of $1.46, beating the estimate of $1.06. With 8.38M shares outstanding, the current market capitalization sits at 96.68B.
A.I.Advisor
published Dividends

BMY paid dividends on August 01, 2025

Bristol-Myers Squibb Co BMY Stock Dividends
А dividend of $0.62 per share was paid with a record date of August 01, 2025, and an ex-dividend date of July 03, 2025. Read more...
A.I. Advisor
published General Information

General Information

a manufacturer of pharmaceuticals products

Industry PharmaceuticalsMajor

Profile
Fundamentals
Details
Industry
Pharmaceuticals Major
Address
Route 206 and Province Line Road
Phone
+1 609 252-4621
Employees
34100
Web
https://www.bms.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
BND73.640.24
+0.33%
Vanguard Total Bond Market ETF
NYF52.090.12
+0.23%
iShares New York Muni Bond ETF
SURE122.560.08
+0.07%
AdvisorShares Insider Advantage ETF
PBJN29.04-0.01
-0.04%
PGIM S&P 500 Buffer 20 ETF - Jun
BKGI37.69-0.06
-0.16%
BNY Mellon Global Infras Inc ETF

BMY and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, BMY has been loosely correlated with PFE. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if BMY jumps, then PFE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BMY
1D Price
Change %
BMY100%
+0.19%
PFE - BMY
51%
Loosely correlated
-0.76%
MRK - BMY
50%
Loosely correlated
-1.52%
GILD - BMY
48%
Loosely correlated
+0.25%
NVS - BMY
44%
Loosely correlated
+1.26%
GSK - BMY
43%
Loosely correlated
+1.03%
More